EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases

Gundogdu, Ahmet; Onder, KAHRAMAN; Firat, Pinar; DOĞAN, RIZA

doi:10.3978/j.issn.2072-1439.2014.04.35

EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases

Gundogdu A. G., Onder S., Firat P., DOĞAN R.

JOURNAL OF THORACIC DISEASE, cilt.6, sa.6, ss.778-784, 2014 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 6 Sayı: 6
Basım Tarihi: 2014
Doi Numarası: 10.3978/j.issn.2072-1439.2014.04.35
Dergi Adı: JOURNAL OF THORACIC DISEASE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.778-784
Anahtar Kelimeler: Lung adenocarcinoma, epidermal growth factor receptor (EGFR), RAS, survival, GROWTH-FACTOR RECEPTOR, ONCOGENE PRODUCT, PROGNOSTIC VALUE, CANCER, EXPRESSION, MUTATIONS, FREQUENT, MARKERS
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: The impacts of epidermal growth factor receptor (EGFR) immunoexpression and RAS immunoexpression on the survival and prognosis of lung adenocarcinoma patients are debated in the literature.